What is Leerink Partnrs’ Forecast for AXSM Q1 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Axsome Therapeutics in a research note issued on Monday, February 10th. Leerink Partnrs analyst M. Goodman expects that the company will post earnings per share of ($1.48) for the quarter. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.70) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.65) EPS, FY2027 earnings at $3.85 EPS and FY2028 earnings at $9.90 EPS.

A number of other analysts have also commented on the stock. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a research note on Friday, January 24th. Bank of America lifted their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $190.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Robert W. Baird increased their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $147.13.

Axsome Therapeutics Trading Down 0.5 %

NASDAQ AXSM opened at $131.55 on Wednesday. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $134.18. The business has a 50 day moving average price of $96.55 and a 200-day moving average price of $92.67. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The company has a market cap of $6.37 billion, a price-to-earnings ratio of -20.15 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period in the previous year, the company posted ($1.32) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning raised its holdings in shares of Axsome Therapeutics by 29.8% in the 3rd quarter. Creative Planning now owns 10,854 shares of the company’s stock worth $975,000 after purchasing an additional 2,489 shares during the period. Values First Advisors Inc. purchased a new stake in Axsome Therapeutics in the third quarter worth $568,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after acquiring an additional 318 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Axsome Therapeutics by 4.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 19,808 shares of the company’s stock worth $1,780,000 after acquiring an additional 754 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Axsome Therapeutics by 65.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,232 shares of the company’s stock valued at $830,000 after acquiring an additional 3,652 shares during the period. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.